Partnerships with fellow nonprofits in dermatology and psoriasis allow us to share our knowledge, collaborate on important projects, and collectively advocate for improved treatment of patients worldwide.
The International Federation of Psoriasis Associations (IFPA) is a non-profit organization uniting national and regional psoriasis associations from around the world.
Officially founded in 1935, the International League of Dermatological Societies (ILDS) has been promoting skin health around the world for over 80 years. Its forerunner began in 1889 as the first of many World Congresses of Dermatology. Today, the ILDS represents dermatology at the highest level with over 170 Member Societies from more than 80 countries, we represent over 150,000 dermatologists.
Founded in late 2014, the International Eczema Council (IEC) is a global nonprofit organization led by dermatology experts on atopic dermatitis. The IEC is dedicated to increasing the understanding of atopic dermatitis and promoting its optimal management through research, education and patient/family care.
The European Medicines Agency (EMA) is a decentralised agency of the European Union (EU) responsible for the scientific evaluation, supervision and safety monitoring of medicines in the EU.
UPCOMING EVENT Hot topics and challenging cases in psoriasis: A focus on pustular, biosimilars, pediatrics and treating in under-served areas Monday, june 10, 2019 1:30 – 4:30 pm milan, italy Register Now
IPC Psoriasis Review Newsletter IPC's bi-annual review of the latest manuscripts in the field of psoriasis. Read the latest issue
IPC's bi-annual review of the latest manuscripts in the field of psoriasis.
Psoriasis News Lilly to Present 5-Year Sustained Efficacy and Safety Results for Taltz® (ixekizumab) in Patients with Plaque Psoriasis at the World Congress of Dermatology6/11/2019 9:58:00 AM Review of international psoriasis guidelines for the treatment of psoriasis: recommendations for topical corticosteroid treatments6/5/2019 12:03:00 PMCorticosteroid therapy is regarded as first-line therapy for treating mild psoriasis and recalcitrant lesions. Members of the IPC Topical Therapies Working Group reviewed available international topical corticosteroids guidelines in order to understand current information and to identify areas that would benefit from greater practical guidance for dermatologists. FDA Approves ETICOVO™ (etanercept-ykro), Samsung Bioepis' Second Anti-TNF Medicine in the United States4/29/2019 7:28:00 AM AbbVie Announces Approval of SKYRIZI™ for the Treatment of Psoriasis in US, Canada, Europe and Japan4/28/2019 8:26:00 PM More News